Medical Device Industry News
In May 2022, scientists from the University of Louisville (Departments of Cardiovascular and Thoracic Surgery, Bioengineering, Anesthesiology, and Perioperative Medicine), Veritium research LLC, and Inspired Therapeutics LLC tested the NeoMate mechanical circulatory support (MCS) system for neonates and infants. The complete manuscript by Gretel Monreal, Steven C. Koenig, Mark S. Slaughter, Gino F. Morello, Steven R. Prina, Landon H. Tompkins, Jiapeng Huang, Barry N. Gellman, and Kurt A. Dasse can be found in Plos One. Their research is summarized below.
Up to 14,000 US children are hospitalized yearly with heart failure (HF)-related conditions. These children show a mortality rate of 7-15%, while the mortality rate of those on the waiting list for a heart transplant ranges from 5-39%. Because of these statistics, temporary and durable mechanical circulatory support devices prove to be important in supporting this patient population.
In February 2022, researchers from Seattle Children’s Hospital and the University of Washington School of Medicine took an in-depth look at health simulation, its economic impact, and significant hurdles to its widespread acceptance. The full manuscript, written by Taylor Sawyer, Megan M. Gray, and Rachel Umoren, is available on the Cureus website. Below is a summary of their findings.
An expanding area of healthcare involves simulation, a technique that allows for improved practice, learning, evaluation, or understanding of human actions or systems without endangering real-life patients. The benefits of healthcare simulation include improvements in patient clinical care and outcome, leading to its rapid growth over the last decade.
The review by Sawyer et al. predicts a continued expansion of the global healthcare simulation market’s products and services. A 2019 estimate of the worldwide healthcare simulation market placed its value between $1.42 to 2.27 billion, while the market is projected to reach $3.19 to $7.7 billion by 2027.
An editorial published in April 2022 discusses the benefits and pitfalls of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) combined with intra-aortic balloon pumps (IABP) to manage CS. The complete manuscript, written by Agam Bansal, Dhiran Verghese, and Sarachandra Vallabhajosyula, can be found in the Journal of the American Heart Association. A summary of the editorial is detailed below.
Biological processes utilization for industrial and other applications, notably gene modification of microbes for the synthesis of hormones and antibiotics is Biotechnology.
Valvular heart diseases (VHD) that cause stenosis and regurgitation in heart valves, such as congenital, rheumatic, and degenerative heart illnesses, require constant clinical monitoring. Aortic or pulmonary valve anomalies are responsible for 33% of congenital heart disorders. Although patients with VHD have received transcatheter therapies and minimally invasive operations, the bulk of valve replacement surgeries still use open-heart techniques.
It's difficult to strike a balance between systemic anticoagulation and clotting. The endothelium manages the equilibrium between anticoagulant and prothrombotic systems in proper hemostasis. Because of the blood-surface interaction during ECLS, systemic anticoagulation is required to reduce the risk of clotting. UNFH has a short half-life, is easy to titrate at the bedside, and is reversible with protamine.
According to this article diabetes mellitus (DM) significantly affects mortality and morbidity for cardiovascular procedures and ailments. The authors analysed data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Registry.